4'-(Trifluoromethyl)-1,1'-biphenyl-2-carboxamide | 91748-20-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4'-(Trifluoromethyl)-1,1'-biphenyl-2-carboxamide
• 英文别名: 2-[4-(trifluoromethyl)phenyl]benzamide
• CAS: 91748-20-8
• 化学式: C₁₄H₁₀F₃NO
• 分子量: 265.23
• InChiKey: IPDRRTURNBKLIH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  43.1
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  N-{4-[(2E)-3-(2-pyridinyl)-2-propenoyl]phenyl}-4'-(trifluoromethyl)-1,1'-biphenyl-2-carboxamide 、 氢气 在 钯 silica gel 、 乙酸乙酯 、 正己烷 、 异丙醚 、 4-[3-(2-pyridinyl)propanoyl]phenyl 作用下， 以 甲醇 、 四氢呋喃 为溶剂， 25.0 ℃ 、13.51 MPa 条件下， 反应 4.0h， 以to give N-≡4-[3-(2-pyridinyl)propanoyl]phenyl}-4′-(trifluoromethyl)-1,1′-biphenyl-2-carboxamide (2.54 g)的产率得到4'-(Trifluoromethyl)-1,1'-biphenyl-2-carboxamide
  参考文献：
  名称：

  Benzamide compounds as apo b secretion inhibitors

  摘要：

  本发明涉及式（I）的化合物，其中R1和R2各自独立地为较低的烷基、较低的烯基、酰基、氨基、较低的烷氧基、较低的环烷氧基、芳基、芳氧基、磺酰氧基、巯基、磺酸基、氢、卤素、硝基、氰基或羟基，或可形成环结构；Q1为N或CH；L为可选的取代的不饱和3到10元杂环基；X为可选的取代的单环芳烃基或单环杂芳烃基；Y为-(A1)m-(A2)n-(A4)k-；Z为直接键，-CH2-，-NH-或-O-；R为氢或较低的烷基，或其盐。本发明的化合物抑制载脂蛋白B（Apo B）的分泌，并可用作预防和治疗因循环Apo B水平升高而导致的疾病或病症的药物。

  公开号：

  US20040058903A1

文献信息

• [EN] SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS<br/>[FR] HYDANTOÏNAMIDES SUBSTITUÉS UTILISÉS EN TANT QU'ANTAGONISTES D'ADAMTS7
  申请人：BAYER AG

  公开号：WO2021094436A1

  公开（公告）日：2021-05-20

  The application relates to substituted hydantoinamides of formula (I) as ADAMTS7 antagonists, to processes for their preparation, their use alone or in combination for the treatment or prophylaxis of diseases, in particular of cardiovascular diseases, including atherosclerosis, coronary artery disease (CAD), peripheral vascular disease (PAD), arterial occlusive disease or restenosis after angioplasty. R1 is hydrogen, alkyl, cycloalkyl, heterocycloalkyl, heteroaryl or phenyl; R2 is hydrogen, cyano, halogen, alkylsulfonyl, alkyl, cycloalkyl or alkoxy; R3, R4, R5, R6, R7 and R8 are independently hydrogen, halogen, alkyl or alkoxy; most groups being optionally substituted; with the proviso that at least one of R2, R3, R4 is H; X1, X2, X3, X4, X5 and X6 are independently N or C; with the proviso that in each ring maximal one X is N.

  本申请涉及式(I)所示的取代脒酰胺作为ADAMTS7拮抗剂，涉及它们的制备过程，以及它们单独或组合用于治疗或预防疾病，特别是心血管疾病，包括动脉粥样硬化、冠心病(CAD)、外周血管病(PAD)、动脉闭塞性疾病或血管成形术后的再狭窄。R1是氢、烷基、环烷基、杂环烷基、杂芳基或苯基；R2是氢、氰基、卤素、烷基亚磺酰基、烷基、环烷基或烷氧基；R3、R4、R5、R6、R7和R8独立的是氢、卤素、烷基或烷氧基；大多数基团可被选择性地取代；条件是至少R2、R3、R4中的一个为H；X1、X2、X3、X4、X5和X6独立的是N或C；条件是每个环中最多只有一个X是N。
• Pyridine Derivatives and Their Use as Medicaments for Treating Diseases Related to Mch Receptor
  申请人：Sekiguchi Yoshinori

  公开号：US20080090863A1

  公开（公告）日：2008-04-17

  The present invention encompasses novel substituted pyridine compounds of Formula (I): which act as MCH receptor antagonists. These compositions and pharmaceutical compositions thereof are useful in the prophylaxis or treatment of improving memory function, sleeping and arousal, anxiety, depression, mood disorders, seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorders including bulimia, anorexia, mental disorders including manic depression, schizophrenia, delirium, dementia, stress, cognitive disorders, attention deficit disorder, substance abuse disorders and dyskinesias including Parkinson's disease, epilepsy, and addiction.

  本发明涵盖了式（I）的新型取代吡啶化合物，其作为MCH受体拮抗剂。这些组合物及其制药组合物在预防或治疗改善记忆功能、睡眠和觉醒、焦虑、抑郁、情绪障碍、癫痫、肥胖症、糖尿病、食欲和饮食障碍、心血管疾病、高血压、血脂异常、心肌梗死、暴食障碍，包括贪食症、厌食症、精神障碍，包括躁郁症、精神分裂症、谵妄、痴呆、压力、认知障碍、注意力缺陷障碍、物质滥用障碍和运动障碍，包括帕金森病、癫痫和成瘾方面具有用处。
• CYCLIC VINYLOGOUS AMIDES AS BROMODOMAIN INHIBITORS
  申请人：ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI

  公开号：US20160200666A1

  公开（公告）日：2016-07-14

  Cyclic vinylogous amides of Formula I are disclosed The compounds are useful for treating diseases that arise from inappropriate activity of proteins containing an acetyl-lysine. The compositions comprise a genus of cyclic vinylogous amides that are inhibitors of bromodomain.

  公开了公式I的环状乙烯基酰胺。这些化合物可用于治疗由含有乙酰-赖氨酸蛋白质的不适当活性引起的疾病。该组合物包括一类环状乙烯基酰胺，其是溴域的抑制剂，可用于治疗上述疾病。
• Benzoic acid derivatives
  申请人：THE WELLCOME FOUNDATION LIMITED

  公开号：EP0106140A2

  公开（公告）日：1984-04-25

  2-(4-Substituted phenyl)-2-benzoic acid derivatives, methods for their preparation, pharmaceutical formulations containing the compounds and the use thereof in the reduction or control of blood lipids in animals, including man, are disclosed. Preferred compounds are esters of 2-(4-trifluoromethylphenyl)benzoic acid.

  本发明公开了 2-(4-取代苯基)-2-苯甲酸衍生物、其制备方法、含有该化合物的药物制剂及其在降低或控制动物（包括人类）血脂中的用途。首选化合物是 2-(4-三氟甲基苯基)苯甲酸的酯类。
• SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS
  申请人：Bayer Aktiengesellschaft

  公开号：EP3822268A1

  公开（公告）日：2021-05-19

  The application relates to substituted hydantoinamides of formula (I) as ADAMTS7 antagonists, to processes for their preparation, their use alone or in combination for the treatment or prophylaxis of diseases, in particular of cardiovascular diseases, including atherosclerosis, coronary artery disease (CAD), peripheral vascular disease (PAD), arterial occlusive disease or restenosis after angioplasty. R 1 is hydrogen, alkyl, cycloalkyl, 5- to 6-membered heterocycloalkyl, 5- to 10-membered heteroaryl or phenyl; R 2 is hydrogen, cyano, halogen, alkylsulfonyl, alkyl, cycloalkyl or alkoxy; R 3 , R 4 , R 5 , R 6 , R 7 , R 8 are independently hydrogen, halogen, alkyl or alkoxy; most groups being optionally substituted; with the proviso that at least one of R 2 , R 3 , R 4 is H; X 1 , X 2 , X 3 , X 4 , X 5 , X 6 are independently N or C; with the proviso that in each ring maximal one X is N.

  本申请涉及作为 ADAMTS7 拮抗剂的式 (I) 取代的 hydantoinamides、其制备工艺、单独使用或联合使用以治疗或预防疾病，特别是心血管疾病，包括动脉粥样硬化、冠状动脉疾病 (CAD)、外周血管疾病 (PAD)、动脉闭塞性疾病或血管成形术后再狭窄。 R 1 是氢、烷基、环烷基、5-6 元杂环烷基、5-10 元杂芳基或苯基；R 2 是氢、氰基、卤素、烷基磺酰基、烷基、环烷基或烷氧基；R 3、R 4、R 5、R 6、R 7、R 8 独立地是氢、卤素、烷基或烷氧基；X1、X2、X3、X4、X5、X6 独立地为 N 或 C，但每个环中最多一个 X 为 N。